AstraZeneca
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer
Phase 3
Completed
- Conditions
- Non-Metastatic Prostate Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3588
- Registration Number
- NCT00673205
- Locations
- π¬π§
Research Site, Shrewsbury, United Kingdom
Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
Phase 2
Completed
- Conditions
- OverweightObesity
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 636
- Registration Number
- NCT00673387
- Locations
- πΊπΈ
Research Site, Olympia, Washington, United States
Electrophysiological Effects of a Single 10 ΞΌg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 70
- Registration Number
- NCT00672399
- Locations
- π¬π§
Reseach Site, Derriford, Plymouth, United Kingdom
π¬π§Research Site, Leeds, West Yorkshire, United Kingdom
Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder
Phase 4
Completed
- Conditions
- Acute Mania in Bipolar Disorder
- Interventions
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2012-07-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 376
- Registration Number
- NCT00672490
- Locations
- π¨π³
Research Site, Huzhou, Zhejiang, China
Casodex vs Placebo in Non-Metastatic Early Prostate Cancer
Phase 3
Completed
- Conditions
- Non-Metastatic Prostate Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2009-05-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1218
- Registration Number
- NCT00672282
- Locations
- πΈπͺ
Research Site, Vostervik, Sweden
Pharmacokinetics, Safety & Tolerability of ZD4054 (Zibotentan) in Subjects With Normal, Mild, Moderate and Severe Hepatic Impairment
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2010-09-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT00672581
- Locations
- π¨πΏ
Research Site, Praha 6, Czech Republic
Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1386
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 103
- Registration Number
- NCT00672646
- Locations
- πΊπΈ
Research Site, Salt Lake City, Utah, United States
Factors of Importance for the Subjective and Objective Burden of Informal Caregivers to Patients With Functional Psychoses - a Descriptive and Comparative Study
Completed
- Conditions
- Functional PsychosesInformal Caregivers
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2009-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00670371
- Locations
- πΈπͺ
Research Site, Stockholm, Sweden
πΈπͺResearch site, Bromma, Sweden
Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2010-08-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00669903
- Locations
- πΊπΈ
Research Center, Glendale, California, United States
Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 99
- Registration Number
- NCT00667992
- Locations
- π¬π§
Research Site, Perth, Scotland, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath